0001179110-17-009806.txt : 20170629
0001179110-17-009806.hdr.sgml : 20170629
20170629213340
ACCESSION NUMBER: 0001179110-17-009806
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170627
FILED AS OF DATE: 20170629
DATE AS OF CHANGE: 20170629
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics AG
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: C4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: LEBERSTRASSE 20
CITY: VIENNA
STATE: C4
ZIP: 1110
BUSINESS PHONE: 43 (0)1 740 93-0
MAIL ADDRESS:
STREET 1: LEBERSTRASSE 20
CITY: VIENNA
STATE: C4
ZIP: 1110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HBM Healthcare Investments (Cayman) Ltd.
CENTRAL INDEX KEY: 0001232258
STATE OF INCORPORATION: E9
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 17940052
BUSINESS ADDRESS:
STREET 1: 2454 WEST BAY ROAD, 3RD FLOOR
CITY: GRAND CAYMAN
STATE: E9
ZIP: 00000
BUSINESS PHONE: 1 345 946 8002
MAIL ADDRESS:
STREET 1: P.O BOX 30852
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1204
FORMER NAME:
FORMER CONFORMED NAME: HBM BIOVENTURES CAYMAN LTD
DATE OF NAME CHANGE: 20030512
4
1
edgar.xml
FORM 4 -
X0306
4
2017-06-27
0
0001641640
Nabriva Therapeutics AG
NBRV
0001232258
HBM Healthcare Investments (Cayman) Ltd.
GOVERNORS SQUARE, SUITE #4-212-2
23 LIME TREE BAY AVE., WEST BAY
GRAND CAYMAN
E9
00000
CAYMAN ISLANDS
0
0
1
0
American Depository Shares representing Common Shares
2017-06-27
4
S
0
2166
10.8297
D
2591396
D
American Depository Shares representing Common Shares
2017-06-28
4
S
0
4789
11.10
D
2586697
D
American Depository Shares representing Common Shares
2017-06-29
4
S
0
1603
10.7230
D
2585004
D
Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs.
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $11.16. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.61 to $10.81. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
/s/ Jean-Marc Lesieur, Managing Director
2017-06-29